Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Enterprise Value: 2010-2025

Historic Enterprise Value for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $3.9 billion.

  • Arrowhead Pharmaceuticals' Enterprise Value rose 124.31% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 141.76%. This contributed to the annual value of $3.9 billion for FY2025, which is 124.31% up from last year.
  • Arrowhead Pharmaceuticals' Enterprise Value amounted to $3.9 billion in Q3 2025, which was up 203.85% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Enterprise Value peaked at $8.2 billion during Q2 2021, and registered a low of $510.0 million during Q1 2025.
  • Its 3-year average for Enterprise Value is $2.4 billion, with a median of $2.5 billion in 2023.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Enterprise Value skyrocketed by 144.02% in 2021, and later crashed by 83.18% in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Enterprise Value stood at $6.8 billion in 2021, then crashed by 43.46% to $3.8 billion in 2022, then dropped by 19.30% to $3.1 billion in 2023, then crashed by 41.89% to $1.8 billion in 2024, then surged by 124.31% to $3.9 billion in 2025.
  • Its last three reported values are $3.9 billion in Q3 2025, $1.3 billion for Q2 2025, and $510.0 million during Q1 2025.